The use of intravitreal bevacizumab in pediatric retinal and uveitic disease has become more widespread over the past decade. This article serves to outline the rationale underlying the use of intravitreal bevacizumab, and which disease entities it should be appropriately thought of as a primary or solo therapy, as opposed to an adjuvant one. Also presented is the relevant literature regarding each of these retinopathies.
SiskRABerrocalAMAlbiniTAet al. Bevacizumab for the treatment of pediatric retinal and choroidal diseases. Ophthalmic Surg Lasers Imaging2010; 41(6): 582–592.
2.
HenryCRSiskRATzuJHet al. Long-term follow-up of intravitreal bevacizumab for the treatment of pediatric retinal and choroidal diseases. J AAPOS2015; 19(6): 541–548.
3.
BouRIglesiasEAntónJ.Treatment of uveitis associated with juvenile idiopathic arthritis. Curr Rheumatol Rep2014; 16(8): 437.
4.
Mintz-HittnerHAGeloneckMMChuangAZ.Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology2016; 123(9): 1845–1855.
5.
WongLJDesaiRUJainAet al. Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. Retina2008; 28(8): 1151–1158.
6.
ShieldsJAShieldsCLHonavarSGet al. Classification and management of Coats disease: the 2000 Proctor lecture. Am J Ophthalmol2001; 131(5): 572–583.
7.
SilodorSWAugsburgerJJShieldsJAet al. Natural history and management of advanced Coats’ disease. Ophthalmic Surg1988; 19(2): 89–93.
8.
HanESChoungHKHeoJWet al. The effects of external subretinal fluid drainage on secondary glaucoma in Coats disease. J AAPOS2006; 10(2): 155–158.
HeYGWangHZhaoBet al. Elevated vascular endothelial growth factor level in Coats’ disease and possible therapeutic role of bevacizumab. Graefes Arch Clin Exp Ophthalmol2010; 248(10): 1519–1521.
14.
ZhangHLiuZL.Increased nitric oxide and vascular endothelial growth factor levels in the aqueous humor of patients with Coats’ disease. J Ocul Pharmacol Ther2012; 28(4): 397–401.
KaseSRaoNAYoshikawaHet al. Expression of vascular endothelial growth factor in eyes with Coats’ disease. Invest Ophthalmol Vis Sci2013; 54(1): 57–62.
17.
ZhaoTWangKMaYet al. Resolution of total retinal detachment in Coats’ disease with intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol2011; 249(11): 1745–1746.
18.
EntezariMRamezaniASafavizadehLet al. Resolution of macular edema in Coats’ disease with intravitreal bevacizumab. Indian J Ophthalmol. 2010; 58(1): 80–82.
19.
VenkateshPMandalSGargS.Management of Coats disease with bevacizumab in 2 patients. Can J Ophthalmol2008; 43(2): 245–246.
20.
ZhengXXJiangYR.The effect of intravitreal bevacizumab injection as the initial treatment for Coats’ disease. Graefes Arch Clin Exp Ophthalmol2014; 252(1): 35–42.
21.
LinCJHwangJFChenYTet al. The effect of intravitreal bevacizumab in the treatment of Coats disease in children. Retina2010; 30(4): 617–622.
22.
CackettPWongDCheungCM.Combined intravitreal bevacizumab and argon laser treatment for Coats’ disease. Acta Ophthalmol2010; 88(2): e48–e49.
HuangYCLaiCCWuWC.Integrating scleral buckling, transscleral drainage of subretinal fluid, intravitreal anti-vascular endothelial growth factor, and laser photocoagulation in stage 3B Coats’ total retinal detachment. Ophthalmic Surg Lasers Imaging Retina2016; 47(9): 865–868.
25.
SeinJTzuJHMurrayTGet al. Treatment of Coats’ disease with combination therapy of intravitreal bevacizumab, laser photocoagulation, and sub-tenon corticosteroids. Ophthalmic Surg Lasers Imaging Retina2016; 47(5): 443–449.
26.
VillegasVMGoldASBerrocalAMet al. Advanced Coats’ disease treated with intravitreal bevacizumab combined with laser vascular ablation. Clin Ophthalmol2014; 8: 973–976.
27.
RamasubramanianAShieldsCL.Bevacizumab for Coats’ disease with exudative retinal detachment and risk of vitreoretinal traction. Br J Ophthalmol2012; 96(3): 356–359.
28.
KaulSUparkarMModyKet al. Intravitreal anti-vascular endothelial growth factor agents as an adjunct in the management of Coats’ disease in children. Indian J Ophthalmol2010; 58(1): 76–78.
29.
StangaPEJaberansariHBindraMSet al. Transcleral drainage of subretinal fluid, anti-vascular endothelial growth factor, and wide-field imaging-guided laser in coats exudative retinal detachment. Retina2016; 36(1): 156–162.
30.
StergiouPKSymeonidisCDimitrakosSA.Coats’ disease: treatment with intravitreal bevacizumab and laser photocoagulation. Acta Ophthalmol2009; 87(6): 687–688.
31.
KodamaASugiokaKKusakaSet al. Combined treatment for Coats’ disease: retinal laser photocoagulation combined with intravitreal bevacizumab injection was effective in two cases. BMC Ophthalmol2014; 14: 36.
32.
RayRBarananoDEHubbardGB.Treatment of Coats’ disease with intravitreal bevacizumab. Br J Ophthalmol2013; 97(3): 272–277.
33.
CakirMCekicOYilmazOF.Combined intravitreal bevacizumab and triamcinolone injection in a child with Coats disease. J AAPOS2008; 12(3): 309–311.
34.
BohmMRUhligCE.Use of intravitreal triamcinolone and bevacizumab in Coats’ disease with central macular edema. Graefes Arch Clin Exp Ophthalmol2011; 249(7): 1099–1101.
35.
ScottAW.Ophthalmic manifestations of sickle cell disease. South Med J2016; 109(9): 542–548.
36.
PahlDAGreenNSBhatiaMet al. New ways to detect pediatric sickle cell retinopathy: a comprehensive review. J Pediatr Hematol Oncol2017; 39(8): 618–625.
37.
MyintKTSahooSMoeSet al. Laser therapy for retinopathy in sickle cell disease. Cochrane Database Syst Rev2013; 10: CD010790.
38.
SiqueiraRCCostaRAScottIUet al. Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy. Acta Ophthalmol Scand2006; 84(6): 834–835.
39.
ShaikhS.Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy. Indian J Ophthalmol2008; 56(3): 259.
40.
BabalolaOE.Intravitreal bevacizumab (Avastin) associated with secondary hyphaema in a case of proliferative sickle cell retinopathy. BMJ Case Rep. Epub ahead of print 30 March 2010. DOI: 10.1136/bcr.11.2009.2441.
PendergastSDTreseMT.Familial exudative vitreoretinopathy: results of surgical management. Ophthalmology1998; 105(6): 1015–1023.
44.
FeiPYangWZhangQet al. Surgical management of advanced familial exudative vitreoretinopathy with complications. Retina2016; 36(8): 1480–1485.
45.
VanRaayTJVetterML.Wnt/frizzled signaling during vertebrate retinal development. Dev Neurosci2004; 26(5–6): 352–358.
46.
SivaprasadSMooreAT.Choroidal neovascularisation in children. Br J Ophthalmol2008; 92(4): 451–454.
47.
RishiPGuptaARishiEet al. Choroidal neovascularization in 36 eyes of children and adolescents. Eye2013; 27(10): 1158–1168.
48.
SundaramNUparkarMAthaleAet al. Intravitreal bevacizumab (Avastin) in a pediatric case of pathologic myopia. Retin Cases Brief Rep2007; 1(4): 192–194.
49.
SalmanAG.Intravitreal bevacizumab for pediatric exudative retinal diseases. Saudi J Ophthalmol2011; 25(2): 193–197.
50.
AgarwalMKanthaMMayorRet al. Bilateral choroidal osteoma with choroidal neovascular membrane treated with bevacizumab in a child. Middle East Afr J Ophthalmol2014; 21(3): 265–267.
51.
PiermarocchiSBenettiEFracassoG.Intravitreal bevacizumab for posttraumatic choroidal neovascularization in a child. J AAPOS2011; 15(3): 314–316.
52.
RishiPRishiEVenkatramanA.Intravitreal bevacizumab for treatment of choroidal neovascularization associated with osteogenesis imperfecta. Indian J Ophthalmol2012; 60(3): 229–231.
53.
BelliveauMJXingLAlmeidaDRet al. Peripapillary choroidal neovascular membrane in a teenage boy: presenting feature of idiopathic intracranial hypertension and resolution with intravitreal bevacizumab. J Neuroophthalmol2013; 33(1): 48–50.
54.
MathurGGeorgeAESenP.Paediatric choroidal neovascular membrane secondary to toxoplasmosis treated successfully with anti-vascular endothelial growth factor. Oman J Ophthalmol2014; 7(3): 141–143.
55.
KohlyRPMuniRHKertesPJet al. Management of pediatric choroidal neovascular membranes with intravitreal anti-VEGF agents: a retrospective consecutive case series. Can J Ophthalmol2011; 46(1): 46–50.
56.
KhanMADeCroosFCStoreyPPet al. Outcomes of anti-vascular endothelial growth factor therapy in the management of choroidal neovascularization associated with choroidal osteoma. Retina2014; 34(9): 1750–1756.
57.
CeleaCPopMAvidis-ZamfiroiuNet al. Evolution of choroidal neovascular membrane in best disease after single intravitreal bevacizumab. Maedica2015; 10(1): 61–64.
58.
HussainRNShahidFLEmpeslidisTet al. Use of intravitreal bevacizumab in a 9-year-old child with choroidal neovascularization associated with autosomal recessive bestrophinopathy. Ophthalmic Genet2015; 36(3): 265–269.
59.
LatanzaLViscogliosiFSolimeoAet al. Choroidal neovascularisation as an unusual ophthalmic manifestation of cat-scratch disease in an 8-year-old girl. Int Ophthalmol2015; 35(5): 709–716.
60.
GrewalDSTran-VietDVajzovicLet al. Association of pediatric choroidal neovascular membranes at the temporal edge of optic nerve and retinochoroidal coloboma. Am J Ophthalmol2017; 174: 104–112.
61.
KozakIMansourADiazRIet al. Outcomes of treatment of pediatric choroidal neovascularization with intravitreal antiangiogenic agents: the results of the KKESH International Collaborative Retina Study Group. Retina2014; 34(10): 2044–2052.
62.
NussenblattRBKaufmanSCPalestineAGet al. Macular thickening and visual acuity: measurement in patients with cystoid macular edema. Ophthalmology1987; 94(9): 1134–1139.
63.
GolanSLoewensteinA.Surgical treatment for macular edema. Semin Ophthalmol2014; 29(4): 242–256.
64.
GilbertC.Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev2008; 84(2): 77–82.
65.
HeidaryGVanderveenDSmithLE.Retinopathy of prematurity: current concepts in molecular pathogenesis. Semin Ophthalmol2009; 24(2): 77–81.
66.
Early Treatment of Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity. Arch Ophthalmol2003; 121: 1684–1696.
67.
DortaPKychenthalA.Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin). Retina2010; 30(4 Suppl.): S24–S31.
68.
SahinASahinMCinguAKet al. Intravitreal bevacizumab monotherapy for retinopathy of prematurity. Pediatr Int2013; 55(5): 599–603.
69.
NicoaraSDNascutzyCCristianCet al. Outcomes and prognostic factors of intravitreal bevacizumab monotherapy in zone I stage 3+ and aggressive posterior retinopathy of prematurity. J Ophthalmol2015; 2015: 102582.
70.
Larranaga-FragosoPPeraltaJBravo-LjubeticLet al. Intravitreal bevacizumab for zone II retinopathy of prematurity. J Pediatr Ophthalmol Strabismus2016; 53(6): 375–382.
71.
ZhangGYangMZengJet al. Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity. Retina2016; 37: 710–717.
72.
WallaceDKKrakerRTFreedmanSFet al. Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study. JAMA Ophthalmol2017; 135(6): 654–656.
73.
QuinnGEDobsonVKivlinJet al. Prevalence of myopia between 3 months and 5½ years in preterm infants with and without retinopathy of prematurity. Ophthalmology1998; 105(7): 1292–1300.
74.
QuinnGEDobsonVDavittBVet al. Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings to 3 years of age. Ophthalmology2008; 115(6): 1058–1064.e1.
75.
GeloneckMMChuangAZClarkWLet al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol2014; 132(11): 1327–1333.
76.
Mintz-HittnerHAGeloneckMM.Review of effects of anti-VEGF treatment on refractive error. Eye Brain2016; 8: 135–140.
77.
HarderBCSchlichtenbredeFCvonBaltzSet al. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol2013; 155(6): 1119–1124.e1.
78.
HwangCKHubbardGBHutchinsonAKet al. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology2015; 122(5): 1008–1015.
79.
IsaacMMireskandariKTehraniN.Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser. J AAPOS2015; 19(2): 140–144.
80.
WangJXiangD.Early clinical characteristics of bacterial endophthalmitis in retinopathy of prematurity after intravitreal bevacizumab injection: a case report. Exp Ther Med2017; 13(6): 3563–3566.
81.
LeporeDQuinnGEMolleFet al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology2014; 121(11): 2212–2219.
82.
WuWCYehPTChenSNet al. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan. Ophthalmology2011; 118(1): 176–183.
83.
SnyderLLGarcia-GonzalezJMShapiroMJet al. Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging Retina2016; 47(3): 280–283.
84.
SatoTWadaKArahoriHet al. Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol2012; 153(2): 327–333.e1.
85.
LienRYuMHHsuKHet al. Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment. PLoS ONE2016; 11(1): e0148019.
86.
MorinJLuuTMSupersteinRet al. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics2016; 137(4): e20153218.
87.
SankarMJSankarJMehtaMet al. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev2016; 2: CD009734.
